Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: Voxelotor for Leg Ulcers in Sickle Cell Disease
NCT05561140Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) and leg ulcer comparing Voxelotor + SOC with Placebo + SOC (2 arms). Primary endpoint: Percentage of Participants Who Achieved Resolution of the Target Ulcers at 12 weeks. Started May 2022; status: terminated.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)leg ulcer
Beyond the preview
Go deeper on NCT05561140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561140.